Coronary Care Unit, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Arch Cardiol Mex. 2023;93(1):4-12. doi: 10.24875/ACM.21000312.
The objective of the study was to analyze the differences between survivors and non-survivors with non-reperfused ST-segment elevation myocardial infarction (STEMI) and to identify the predictors of in-hospital mortality.
A retrospective cohort study included non-reperfused STEMI patients from October 2005 to August 2020. Patients were classified into survivors and non-survivors. We compared patient characteristics, treatments, and outcomes among the groups and identified factors associated with in-hospital mortality.
We included 2442 patients with non-reperfused STEMI and we found a mortality of 12.7% versus 7.2% in reperfused STEMI. The main reason for non-reperfusion was delayed presentation (96.1%). Non-survivors were older, more often women, and had diabetes, hypertension, or atrial fibrillation. The left main coronary disease was more frequent in non-survivors as well as three-vessel disease. Non-survivors developed more in-hospital heart failure, reinfarction, atrioventricular block, bleeding, stroke, and death. The main predictors for in-hospital mortality were renal dysfunction (HR 3.41), systolic blood pressure < 100 mmHg (HR 2.26), and left ventricle ejection fraction < 40% (HR 1.97).
Mortality and adverse outcomes occur more frequently in non-reperfused STEMI. Non-survivors tend to be older, with more comorbidities, and have more adverse in-hospital outcomes.
本研究旨在分析未再灌注 ST 段抬高型心肌梗死(STEMI)患者的幸存者与非幸存者之间的差异,并确定院内死亡的预测因素。
本回顾性队列研究纳入了 2005 年 10 月至 2020 年 8 月期间的非再灌注 STEMI 患者。患者分为幸存者和非幸存者。我们比较了各组患者的特征、治疗方法和结局,并确定了与院内死亡相关的因素。
共纳入 2442 例非再灌注 STEMI 患者,其中再灌注 STEMI 的死亡率为 7.2%,而非再灌注 STEMI 的死亡率为 12.7%。非再灌注的主要原因是延迟就诊(96.1%)。非幸存者年龄较大,女性较多,且患有糖尿病、高血压或心房颤动。非幸存者的左主干冠状动脉疾病和三血管疾病更为常见。非幸存者更易发生院内心力衰竭、再梗死、房室传导阻滞、出血、卒中和死亡。院内死亡的主要预测因素包括肾功能不全(HR 3.41)、收缩压<100mmHg(HR 2.26)和左心室射血分数<40%(HR 1.97)。
非再灌注 STEMI 患者的死亡率和不良结局更为常见。非幸存者往往年龄较大,合并症较多,且院内不良结局更多。